Immunic, Inc. IMUX

Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will...

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on Wednesday, September 9, 2026, at 11:00 am ET.

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Chitrang Davé as Chief Data and Digital Officer (CDDO), effective today. Mr. Davé will report directly to Chief Executive Officer Erik Lundgren and will serve as a member of the executive leadership team.

Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage development in multiple sclerosis, while expanding its leadership team ahead of potential regulatory filings and...

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Elena Ridloff to its board of directors, the biotechnology company said Monday. Ridloff currently serves as CFO at Sionna Therapeutics. She previously held the same role at ACADIA Pharmaceuticals, where she helped raise $600 million in capital and...

Immunic Inc (NASDAQ:IMUX, FRA:10VA) CEO Erik Lundgren spoke with Proactive's Stephen Gunnion about the company's second-quarter results, its leadership transition and the milestones set to shape the next phase of its multiple sclerosis (MS) programme. Lundgren explained why he joined Immunic, pointing to the potential of lead candidate vidofludimus calcium and the chance to lead the business into two pivotal Phase 3 readouts. Both the ENSURE-1 and ENSURE-2 Phase 3 studies in relapsing MS are fully enrolled and on track to report results by year-end, with the company already engaging health aut

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in July:

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June:

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, North Carolina, including a late-breaking analysis of its lead drug candidate vidofludimus calcium in patients with progressive...

Immunic, Inc.(Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the presentation of one late-breaking and two additional posters highlighting additional data from its phase 2 CALLIPER trial evaluating lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis (PMS) at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annu

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its CEO as the company advances its multiple sclerosis treatment candidate through late-stage development and prepares for potential commercialization. Lundgren succeeds Daniel Vitt, who will continue...

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of distinguished biopharmaceutical executive Erik Lundgren as Chief Executive Officer, effective May 22, 2026, with employment beginning on June 1, 2026. Mr. Lundgren succeeds Daniel Vitt, Ph.D., who will retain responsibility for scientific strategy and portfolio advancement while remaining a member of Immunic's Board of Dir

Immunic, Inc (NASDAQ:IMUX) announced it strengthened its leadership team on Wednesday as the company prepares to advance its multiple sclerosis pipeline through late-stage development and potential commercialization. Immunic Appoints Erik Lundgren As CEO Immunic named biopharmaceutical executive Erik Lundgren as CEO effective May 22, 2026, with his employment beginning June 1. Lundgren succeeds Daniel Vitt, Ph.D., who will continue overseeing scientific strategy and portfolio advancement while r

Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including...

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" W. Bonney, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective May 16, 2026. Simona Skerjanec, M.Pharm, MBA, will transition from Interim Chairperson to continue serving as a member of the Board.

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...